Pfizer Inc. $PFE Holdings Boosted by Coerente Capital Management

Coerente Capital Management boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 660,614 shares of the biopharmaceutical company’s stock after purchasing an additional 59,397 shares during the period. Pfizer accounts for 2.9% of Coerente Capital Management’s investment portfolio, making the stock its 17th biggest holding. Coerente Capital Management’s holdings in Pfizer were worth $16,013,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Pacer Advisors Inc. grew its holdings in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi grew its holdings in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $389,861,000. Goldman Sachs Group Inc. grew its holdings in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PFE shares. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Stock Performance

NYSE:PFE opened at $25.22 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.08. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $143.39 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.84 and a beta of 0.55. The firm has a 50-day moving average price of $24.83 and a 200 day moving average price of $24.14.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.